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Summary. Background: Binding of protein C (PC) to the
endothelial cell PC receptor (EPCR) stimulates PC activation
by increasing the aﬃnity of PC for the thrombin-thrombo-
modulin complex. A soluble form of this receptor (sEPCR)
circulates in plasma and inhibits both PC activation and APC
anticoagulant activity.Objectives: The aim of this study was to
investigate whether variations in the EPCR gene or plasma
sEPCR levels are risk factors for deep venous thrombosis
(DVT). Patients/methods: In a large case-control study, the
Leiden Thrombophilia Study (LETS), sEPCR levels were
measured by ELISA. All subjects were genotyped for three
haplotype-tagging SNPs, enabling us to detect all four common
haplotypes of the EPCR gene. Results: The distribution of
sEPCR levels in the control population was trimodal and was
genetically controlled by haplotype 3 (H3). This haplotype
explained 86.5% of the variation in sEPCR levels. Carriers of
two H3 alleles had higher sEPCR levels (439 ng mL)1) than
carriers of oneH3 allele (258 ng mL)1), which had higher levels
than non-H3 carriers (94 ng mL)1). Haplotype 4 was associ-
ated with a slightly increased risk (OR ¼ 1.4, 95%CI:1.0–2.2).
The risk of subjects with sEPCR levels in the top quartile
(‡ 137 ng mL)1) was increased compared to that of subjects in
the ﬁrst quartile (< 81 ng mL)1), but since there was no dose–
response eﬀect, it ismost likely that low sEPCR levels reduce the
risk of DVT. Conclusions: Our data do not suggest a strong
associationbetweenEPCRhaplotypes and thrombosis risk, but
low sEPCR levels appear to reduce the risk of DVT.
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Introduction
The protein C pathway is a physiologically important mech-
anism for the regulation of the coagulation process. The
pathway is triggered when thrombin binds to the endothelial
cell surface receptor thrombomodulin. The thrombin-throm-
bomodulin complex activates protein C. Activated protein C
(APC), together with its cofactor protein S, limits the ampli-
ﬁcation and progression of the coagulation cascade by
proteolytic inactivation of factors (F)Va and FVIIIa [1]. This
process occurs on the negatively charged surface of activated
platelets [2,3].
In 1994, an endothelial cell-speciﬁc protein C binding protein
called endothelial cell protein C receptor (EPCR) was identiﬁed
[4]. This receptor is a type I transmembrane protein that is
almost exclusively expressed on the endotheliumof large vessels
[5]. Binding of protein C to EPCR stimulates protein C
activation by increasing the afﬁnity of protein C for the
thrombin-thrombomodulin complex. EPCR can bind protein
C and APC with similar afﬁnities [3,6].
EPCR is similar to molecules of the class I major
histocompatibility complex, in particular the CD1-subfamily.
In addition to the a1 and a2 extracellular domains, EPCR has
a transmembrane domain and a very short cytoplasmic tail
[4,7]. The EPCR gene spans approximately 6 kb and is
located on chromosome 20q11.2. It consists of four exons.
Exon 1 (amino acids 1–24) encodes the 5¢ untranslated region
(UTR), the signal peptide, and seven additional residues.
Exons 2 (amino acids 24–108) and 3 (amino acids 108–201)
encode most of the extracellular region of EPCR. Exon 4
(amino acids 201–238) encodes an additional 10 residues of
the extracellular region of EPCR, the transmembrane domain,
the cytoplasmic tail, and the 3¢ UTR [8]. Several variations in
the EPCR gene have been reported, among which a rare
23 bp insertion in exon 3 (position 6367), a polymorphism in
intron 2 (C6333T), a polymorphism in exon 3 (C6622T) and a
polymorphism in exon 4 (A6936G), which predicts an amino
acid change (Ser219Gly) in the transmembrane region of the
receptor (numbering according to GenBank accession number
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AF106202) [9,10]. Another polymorphism (G7014C) was
identiﬁed in the 3¢ UTR, of which the C-allele was reported
to be associated with high levels of circulating APC and a
reduced risk of deep venous thrombosis (DVT) [11,12].
Metalloprotease activity results in cleavage of the entire
extracellular domain of EPCR [13]. The resulting soluble
EPCR (sEPCR) retains its afﬁnity for both protein C and
APC, but now inhibits APC anticoagulant activity by
blocking the interaction of protein C and APC with
negatively charged surfaces [14], an interaction that is
necessary for efﬁcient inactivation of FVa and FVIIIa. In
healthy individuals, plasma sEPCR circulates at a concen-
tration of about 100 ng mL)1. sEPCR levels are increased in
patients with systemic inﬂammatory diseases [15]. Decreased
levels are observed during anticoagulant therapy [16].
Stearns-Kurosawa et al. reported a bimodal distribution of
plasma sEPCR levels. Analyses of the plasma sEPCR levels
of two healthy adult populations from France and Italy
demonstrated that each was different from a Gaussian
distribution [16,17].
The importance of the protein C pathway in the
regulation of ﬁbrin formation is emphasized by the elevated
risk of DVT associated with protein C and protein S
deﬁciencies and the FV Leiden mutation [18]. Therefore we
hypothesized that variations in the EPCR gene or plasma
sEPCR levels inﬂuence the risk of DVT. Mutations in the
gene that lead to a loss of function could lead to decreased
EPCR-activity on the membrane. This is expected to result
in decreased APC formation, less inactivation of FVa and
FVIIIa, more thrombin generation and an increased risk of
thrombosis. On the other hand, overexpression of EPCR
could result in a decreased thrombosis risk. Whether the
level of sEPCR in plasma affects the risk of venous
thrombosis is unclear, although, hypothetically, high as well
as low plasma sEPCR levels may increase this risk. Elevated
plasma sEPCR levels might be associated with a higher
thrombotic risk, because plasma sEPCR inhibits both
protein C activation and APC anticoagulant activity. Also
high plasma sEPCR might result in a low residual EPCR
level on the membrane and thus indicate reduced protein C
activation. In contrast, low plasma sEPCR levels might also
reﬂect low EPCR expression on the endothelium, leading to
decreased APC formation, and thereby to an increased risk
of thrombosis.
Recently, Saposnik et al. reported that a speciﬁc haplotype
of the EPCR gene (A3) is associated with increased plasma
sEPCR levels and is a candidate risk factor for venous
thrombosis [19]. In our study, we identiﬁed the four most
common haplotypes of the EPCR gene and studied their
association with risk of venous thrombosis. The French study
found three haplotypes (A1, A2 and A3) that are identical to
our haplotypes H1, H2 and H3. We describe an additional
haplotype (H4) that was not reported in their study.
Furthermore, we studied various determinants of plasma
sEPCR levels and investigated the association between plasma
sEPCR levels and the development of a ﬁrst DVT. For our
study we used a large population-based case-control study on
risk factors of venous thrombosis, the Leiden Thrombophilia
Study (LETS).
Subjects and methods
Study population
The design of the Leiden Thrombophilia Study (LETS) has
been described in detail previously [20,21]. In short, 474
consecutive patients with an objectively conﬁrmed ﬁrst episode
of deep vein thrombosis and 474 sex- and age-matched controls
were included. The patients were all younger than 70 years and
were not known to have a malignant disorder. Acquaintances
and partners of patients served as controls. The mean age for
patients and controls was 45 years (range 15–69 for patients,
15–72 for controls). Both groups consist of 272 women and 202
men. Venous blood was collected into tubes containing 0.1
volume of 0.106 mol L)1 trisodium citrate. Plasma was
prepared by centrifugation for 10 min at 2000 · g at room
temperature and stored at )70 C. High molecular weight
DNA was isolated from leukocytes by standard methods and
stored at )20 C.
sEPCR antigen measurement
Plasma sEPCR levels were measured by enzyme linked
immuno-sorbent assay (ELISA), according to the manufac-
turer’s instructions. The Asserachrom sEPCR ELISA kits
were kindly provided by Diagnostica Stago (Asnie`res, France).
The assay uses two different monoclonal antibodies against
EPCR as catching and tagging antibody. Samples were diluted
1/26 and assayed in duplicate.
Genetic analysis
In the EPCR gene, four common haplotypes are known
(Fig. 1) [22]. We chose three htSNPs (haplotype-tagging Single
Nucleotide Polymorphisms) to cover the four haplotypes (H1,
H2, H3 and H4) of the EPCR gene. An htSNP is a
polymorphism of which the rare allele is speciﬁc to the
haplotype. One haplotype (H2) consists of the common alleles
of all htSNPs. Genotyping was performed using the 5¢
nuclease/TaqMan assay [23]. The polymerase chain reaction
with ﬂuorescent allele-speciﬁc oligonucleotide probes (Assay-
by-Design/Assay-on-Demand, Applied Biosystems, Foster
City, CA, USA) was performed on a PTC-225 (Biozym,
Hessisch Oldendorf, Germany) and ﬂuorescence endpoint
reading for allelic discrimination was done on an ABI 7900
HT (Applied Biosystems). For these analyses, 471 patient
samples and 471 control samples were studied.
Statistical analysis
Odds ratios (OR) and 95% conﬁdence intervals (95%CI) were
calculated as estimation of the risk of venous thrombosis for
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carriers of the rare allele of each htSNP compared to carriers of
the common allele.Whether variations in plasma sEPCR levels
are a risk factor for venous thrombosis was investigated by
calculating ORs and 95%CIs of the quartiles of plasma sEPCR
levels measured in the control subjects. Putative determinants
of plasma sEPCR levels were investigated in the control
subjects only, who reﬂect the general population. The meas-
urements of FII activity [24], FV:Ag [25], FVII activity [26],
FVIII activity [27], FIX activity [28], FX Ag [29], FXI:Ag [30],
FXII activity [31], FXIII A and B subunit Ag [32], protein C
activity [33], total and free protein S Ag [33], antithrombin
activity [33] and ﬁbrinogen levels [26] have been described
before. To investigate the relationship between sEPCR levels
and oral contraceptive use, an additional selection was made,
as described before [34,35]. Premenopausal control women
aged 15–49 (n ¼ 153) were selected after exclusion of women
who were pregnant (n ¼ 10), within 30 days postpartum (n ¼
14), with a recent miscarriage (n ¼ 2) or who had used only
depot contraceptives (n ¼ 3) at the index date. Because of the
trimodal distribution of the plasma sEPCR levels, we used the
Mann–Whitney non-parametric test for these analyses. To
investigate the association between htSNP A6936G (H3) and
plasma sEPCR levels, mean levels with 95%CIs were calcula-
ted. Forty-eight of the patients and one of the control subjects
were on oral anticoagulant therapy. Use of oral anticoagula-
tion reduced sEPCR levels, conﬁrming previous results [16].
The mean plasma level in the 48 patients using oral anticoag-
ulation wasmuch lower (86.6 ng mL)1) than themean levels in
426 non-users (147.7 ng mL)1). Therefore, oral anticoagula-
tion users were excluded from analyses concerning sEPCR
levels. For these analyses, we studied 426 patients and 472
control subjects. Since three DNA samples were missing, we
could use 469 control subjects for the combined analyses of
sEPCR levels with genotype.
Results
EPCR haplotypes and the risk of venous thrombosis
The genotypes for all three htSNPs could be determined in 471
patients and 471 control subjects. None of the subjects carried
more than two htSNPs, suggesting an absence of recombina-
tion in the EPCR gene. The distribution of the genotypes
among control subjects was as expected for a population in
Hardy–Weinberg equilibrium.
In Table 1, the venous thrombosis risk associated with each
haplotype in the EPCR gene is shown. Carriers of one or two
H1 alleles had a slightly decreased risk (OR ¼ 0.8, 95%CI:
0.6–1.1). H2 andH3were not associatedwith the risk of venous
thrombosis. The group of individuals with either one or twoH4
alleles had a weakly increased risk compared with individuals
without a H4 allele (OR ¼ 1.4, 95%CI: 1.0–2.2).
The risk associated with H4 was not materially affected by
age, as both the younger and older subgroup showed a very
similar risk (< 45: OR ¼ 1.5, 95%CI: 0.9–2.7; ‡ 45: OR ¼
1.4, 95%CI: 0.8–2.4). The risks associated with the other
haplotypes were not affected by age either. When the risk of
developing venous thrombosis was assessed for men and
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Fig. 1 The four haplotypes of the EPCR gene (numbering according to GeneBank accession number AF106202). The polymorphisms with an asterisk are
the selected htSNPs.
Table 1 Thrombosis risk of the four most common haplotypes of the
EPCR gene
Haplotype
(htSNP)
Patients (%)
n ¼ 471
Controls (%)
n ¼ 471 OR 95% CI
H1 (T6333C)
HxHx 192 (40.8) 171 (36.3) 1*
H1Hx 215 (45.6) 231 (49.0) 0.8 0.6–1.1
H1H1 64 (13.6) 69 (14.6) 0.8 0.6–1.2
H1Hx/H1H1 279 (59.2) 300 (63.7) 0.8 0.6–1.1
Frequency H1 36.4 39.2
H2 (all common)
HxHx 157 (33.3) 152 (32.3) 1*
H2Hx 233 (49.5) 234 (49.7) 1.0 0.7–1.3
H2H2 81 (17.2) 85 (18.0) 0.9 0.6–1.4
H2Hx/H2H2 314 (66.7) 319 (67.7) 1.0 0.7–1.3
Frequency H2 41.9 42.9
H3 (A6936G)
HxHx 345 (73.2) 361 (76.6) 1*
H3Hx 116 (24.6) 100 (21.2) 1.2 0.9–1.7
H3H3 10 (2.1) 10 (2.1) 1.1 0.4–2.6
H3Hx/H3H3 126 (26.8) 110 (23.4) 1.2 0.9–1.6
Frequency H3 14.4 12.7
H4 (G6147A)
HxHx 406 (86.2) 424 (90.0) 1*
H4Hx 62 (13.2) 45 (9.6) 1.4 1.0–2.2
H4H4 3 (0.6) 2 (0.4) 1.6 0.3–9.4
H4Hx/H4H4 65 (13.8) 47 (10.0) 1.4 1.0–2.2
Frequency H4 7.2 5.2
*Reference Category; Hx: all haplotypes but the one given.
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women separately, we found that the risk associated with H4
was slightly higher in women (OR ¼ 1.6, 95%CI: 0.9–3.0) than
in men (OR ¼ 1.3, 95%CI: 0.8–2.3). The ORs of the other
haplotypes were not affected by sex.
A total number of 116 patients and 25 control subjects
carried the FV Leiden mutation and/or the prothrombin
20210 A allele. Exclusion of these individuals did not change
the risks associated with the four haplotypes.
Distribution and determinants of sEPCR levels
Figure 2 shows the distribution of sEPCR levels in the group of
healthy controls. The distribution seems to be trimodal. We
investigated the effect of age, sex, oral contraceptive use and
haplotype on this distribution. sEPCR levels were inﬂuenced
most by the EPCR haplotype. The G allele of the htSNP
speciﬁc for H3 (A6936G) was associated with increased plasma
sEPCR levels, as was also observed by Saposnik et al. [19].
Carriers of two 6936 G alleles had higher sEPCR levels than
GA heterozygotes, which had higher levels than AA carriers.
By correlation analysis we found that as much as 86.5% of the
variation in plasma sEPCR levels could be explained by this
polymorphism. The trimodal distribution of sEPCR levels
combined with information on the A6936G genotype in the
group of healthy controls (n ¼ 469) is shown in Fig. 2. The
other haplotypes did not show any effect on plasma sEPCR
levels.
The effect of other putative determinants of plasma sEPCR
levels is shown in Table 2. Men had higher plasma sEPCR
levels than women and individuals older than 45 years had
higher sEPCR levels than individuals younger than 45 years.
The use of oral contraceptives lowered plasma sEPCR levels.
Because sEPCR has the same afﬁnity for both protein C and
APC, we also assessed whether there was an association
between plasma sEPCR and protein C levels. We found that
individuals with protein C levels <101 U dL)1 had lower
sEPCR levels than those with protein C levels ‡ 101 U dL)1
(Table 2). Protein C levels (expressed in U dL)1 [36]) and
sEPCR levels (expressed in ng mL)1) were positively correla-
ted, with a regression coefﬁcient of 1.81 (95%CI: 1.4–2.2).
Other variables such as smoking, body mass index,
C-reactive protein, ABO blood group, levels of other clotting
factors (FII, FV, FVII, FVIII, FIX, FX, FXI, FXII, FXIIIA
subunit, FXIIIB subunit, ﬁbrinogen, protein S, antithrombin)
and D-Dimer had no inﬂuence on plasma sEPCR levels.
Because of the great inﬂuence ofH3on sEPCR levels, we also
investigated the abovementioned determinants in the subgroup
of 6936 A homozygotes. In this group we found similar results.
sEPCR levels and the risk of venous thrombosis
The median plasma sEPCR level in the 426 patients not using
oral anticoagulation was slightly higher (104 ng mL)1) than
themedian in the 472 control subjects (101 ng mL)1). To assess
whether levels of sEPCRwere associated with an increased risk
of DVT, we divided the sEPCR levels into quartiles, as
measured in the healthy control group. As shown in Table 3,
the risk of subjects with plasma sEPCR levels in the top quartile
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Fig. 2 Distribution of sEPCR levels in control subjects, by genotype for A6936G (H3) (n ¼ 469)
Table 2 Determinants of sEPCR levels in healthy controls
Determinants n Median Range P*
Sex
Male 200 111 49–513
Female 272 92 46–500 < 0.0001
Age
< 45 239 96 48–513
‡ 45 233 104 46–479 0.04
Use of oral contraceptives
Yes 54 79 48–513
No 99 91 46–479 0.04
Protein C levels
< 101 232 96 48–513
‡ 101 232 111 46–500 < 0.0001
*P-values obtained after Mann–Whitney test.
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(‡ 137 ng mL)1) was increased compared to that of subjects in
the ﬁrst quartile (< 81 ng mL)1). Taking the ﬁrst quartile as a
reference group, the second and third quartiles also gave
increased ORs, but there was no evidence of a dose–response
relationship. Adjustment for age and sex did not change the
ORs.
Discussion
In this study we investigated the association of the four most
common haplotypes of the EPCR gene with plasma sEPCR
levels and the risk of DVT. We genotyped all subjects of the
LETS for these four haplotypes and measured the plasma
sEPCR levels.
The four most common haplotypes of the EPCR gene were
all present at frequencies above 5% and none was clearly
associated with an increased risk of DVT. Espan˜a et al.
reported that CC homozygotes of a polymorphism (G7014C),
of which the C-allele is speciﬁc for H1, had a 2.6-fold reduced
risk of DVT in a study of 184 cases and 160 controls [11].
However, in the study of Galligan et al. the same polymorph-
ism was not associated with the risk of venous thrombosis in
389 cases and 262 controls [37]. In our study, the risk associated
with H1 was essentially the same as for the other haplotypes,
although a reduced risk could not be excluded. Only H4, which
was not reported in a recent French study [19] was weakly
associated with thrombotic risk. In contrast to the French
study, we found no association of H3with the risk of DVT.We
found a slightly higher frequency of H3 than the French study,
especially in the controls. After exclusion of subjects with the
FV Leiden mutation and the prothrombin 20210 A allele the
risks associated with the four haplotypes did not change.
To determine whether variations in plasma sEPCR levels
inﬂuenced the risk of DVT, the effects were investigated using
various cut-off levels. We found that when compared with the
ﬁrst quartile of plasma sEPCR levels (< 81 ng mL)1) the top
quartile (‡ 137 ng mL)1) was associated with an increased risk
of venous thrombosis. The risk of the 2nd and 3rd quartiles was
also increased relative to that of the ﬁrst quartile. However, the
absence of a gradient of risk over the levels of sEPCR renders it
implausible that the observed increased risk associated with
sEPCR levels ‡ 81 ng mL)1 is a true effect. This would also
explainwhy theH3haplotype,which is associatedwith strongly
elevated sEPCR levels, did not increase the risk of thrombosis.
When we express the results of these analyses in terms of risk
reduction, we found that plasma sEPCR levels below
81 ng mL)1 were associated with a decrease in risk (OR ¼
0.6, 95%CI: 0.4–0.8) when compared to sEPCR levels above
this value. Low plasma sEPCR levels could be the result of an
ineffective or reduced metalloproteolytic cleavage, which keeps
most of the membrane-bound EPCR available for activating
proteinC. It is also possible that low sEPCR levels reﬂect a state
of low thrombin generation (thrombin has been reported to
stimulate sEPCR release in cultured endothelial cells [38]).
In the healthy control subjects, the distribution of the
sEPCR levels was trimodal. High levels of sEPCR were
associated with a speciﬁc haplotype (H3) as reported previously
[19]. This haplotype explains 86.5% of all variation in plasma
sEPCR levels of the control subjects in our study. The
nucleotide change in the polymorphism speciﬁc for H3
(A6936G) results in a Ser to Gly amino acid change in the
transmembrane region of the receptor and predicts a conform-
ational change of the molecule. An explanation for the high
sEPCR levels associated with this haplotype could be that
replacement of Ser219 by Gly introduces a conformational
change in the molecule, which renders the molecule more
susceptible to metalloproteolytic cleavage. Alternatively, it
might affect the distribution of EPCR between the membrane
and intracellular sites. It is also possible that the 6936G is
linked to another variation in H3 which is functional, although
there are presently no obvious candidates (see Fig. 1).
Of the putative determinants of sEPCR levels that were
investigated, protein C had the largest inﬂuence on sEPCR
levels.We found a positive association between protein C levels
and sEPCR levels. It is possible that in plasma sEPCRpartially
circulates in complex with protein C and that the half-life of
these complexes is higher than that of free sEPCR.
In conclusion, we showed that none of the haplotypes of the
EPCR gene is associated with a strong thrombosis risk, but low
sEPCR levels appear to reduce the risk of DVT.
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